Physician profile
Sam Eun Kim
NPI 1093987885
$4,993.68
in general payments reported to CMS, 2019-2025
35 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,340 · 2020: $243 · 2021: $435 · 2022: $348 · 2023: $862 · 2024: $710 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,627 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,626.92 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $756.97 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $562.97 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $466.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $454.41 | 2019-2025 | Repatha, Otezla, Evenity |
| Medtronic, INC. | $263.85 | 2021-2022 | |
| Abbvie INC. | $240.91 | 2020-2025 | |
| Ardelyx, INC. | $233.99 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.24 | 2019-2024 | Synjardy, Jardiance |
| Glaxosmithkline, LLC. | $160.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $150.36 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $124.55 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $123.86 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $123.00 | 2023-2024 | Veozah, Myrbetriq |
| Eisai INC. | $117.29 | 2019-2025 | |
| Amarin Pharma, INC. | $109.77 | 2019 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Eun Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.